Core Viewpoint - Wave Life Sciences Ltd. is set to host a live webcast and conference call on March 4, 2025, to discuss its fourth quarter and full year 2024 financial results and provide business updates [1]. Company Overview - Wave Life Sciences is a clinical-stage biotechnology company focused on RNA medicines aimed at transforming human health [4]. - The company's RNA medicines platform, PRISM, integrates various modalities, chemistry innovations, and insights from human genetics to achieve scientific breakthroughs for treating both rare and common disorders [4]. - Wave's RNA-targeting modalities include editing, splicing, RNA interference, and antisense silencing, which enhance its capabilities in designing and delivering therapeutic candidates [4]. - The company's diversified pipeline includes clinical programs targeting Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and obesity, along with several preclinical programs [4]. - Wave Life Sciences is driven by the mission to "Reimagine Possible," aiming to alleviate the burden of disease on human potential [4].

Core Insights - Wave Life Sciences Ltd. has initiated the Phase 1 INLIGHT clinical trial for WVE-007, a novel GalNAc-siRNA targeting INHBE mRNA, aimed at treating obesity with a focus on healthy weight loss and muscle preservation [1][2] - The company anticipates proof-of-concept clinical data from the INLIGHT trial to be available in 2025, which will include safety, tolerability, and biomarkers for healthy weight loss [2][3] Company Overview - Wave Life Sciences is a clinical-stage biotechnology company focused on RNA medicines, utilizing its PRISM® platform to develop treatments for both rare and common disorders [4] - The company's pipeline includes clinical programs targeting Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington's disease, and obesity, showcasing its diverse approach to RNA therapeutics [4] Product Details - WVE-007 is designed to directly impact fat cells, promoting weight reduction while maintaining muscle mass and improving cardiometabolic health outcomes [2][3] - The mechanism of WVE-007 involves silencing INHBE mRNA, which encodes a protein that inhibits fat burning, thereby potentially inducing a healthier metabolic profile [3] Market Potential - WVE-007 is positioned to address the global obesity epidemic, with over 1 billion individuals affected worldwide, and offers the potential for infrequent dosing (once or twice a year) [2][3]

Core Insights - Wave Life Sciences Ltd. is advancing its RNA medicines platform with significant milestones expected in 2025, focusing on clinical programs for Duchenne Muscular Dystrophy (DMD), Huntington's Disease (HD), Alpha-1 Antitrypsin Deficiency (AATD), and obesity treatments [1][2][11] Clinical Programs - The company has submitted Clinical Trial Applications (CTAs) for the Phase 1 INLIGHT clinical trial of WVE-007, targeting obesity through a novel GalNAc-siRNA approach, with proof-of-concept data anticipated in 2025 [1][3] - WVE-006 has shown promising proof-of-mechanism data in AATD, with a mean total AAT protein increase to 10.8 micromolar, meeting regulatory approval levels for AAT augmentation therapies [7][8] - The FORWARD-53 trial for WVE-N531 in DMD is ongoing, with interim results showing a mean muscle content-adjusted dystrophin expression of 9.0%, and 48-week data expected in Q1 2025 [7][8] - WVE-003, an allele-selective treatment for HD, has demonstrated a reduction in mutant huntingtin protein and preservation of healthy huntingtin, with plans for a registrational Phase 2/3 study [8][13] Pipeline and Future Plans - The company is expanding its GalNAc-AIMer pipeline and plans to share multidose data for WVE-006 in 2025, along with new preclinical data from hepatic and extra-hepatic RNA editing programs [4][7] - Wave expects to initiate clinical development of additional RNA editing programs, including PNPLA3, LDLR, and APOB, in 2026 [7] - The company is well-capitalized, with a cash runway expected to last into 2027, allowing for continued investment in its clinical programs [9] Upcoming Events - The CEO of Wave Life Sciences is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, highlighting the company's advancements and future strategies [10]

Company Overview - Wave Life Sciences Ltd. (NASDAQ: WVE) specializes in developing stereopure oligonucleotides through its PRISM platform, aimed at targeting disease-causing genetic mutations [1] - Stereopure molecules are characterized by precise control over stereochemistry at each chiral center, enhancing both efficacy and safety of the molecules [1] Services Offered - The Total Pharma Tracker provides tools for DIY investors, including a software that allows users to enter any ticker for extensive curated research material [2] - For investors seeking hands-on support, in-house experts analyze tools to identify the best investable stocks, along with buy/sell strategies and alerts [2]

Core Insights - Wave Life Sciences Ltd. has submitted its first clinical trial application (CTA) for WVE-007, an investigational GalNAc-conjugated small interfering RNA (siRNA) aimed at treating obesity by silencing the INHBE gene [4] - The company anticipates approval of the CTA and initiation of the first-in-human study in the first quarter of 2025 [4][8] - WVE-007 is designed to promote fat burning while preserving muscle mass, with the potential for once or twice-annual dosing [5][8] Company Overview - Wave Life Sciences is a clinical-stage biotechnology company focused on RNA medicines, utilizing its PRISM® platform to develop treatments for various disorders [7] - The company’s pipeline includes clinical programs targeting Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency, and Huntington's disease, alongside a preclinical program in obesity [7] Product Details - WVE-007 aims to induce a healthy metabolic profile by silencing the INHBE gene, which has shown promising results in preclinical studies, including weight loss comparable to semaglutide without muscle loss [5][6] - In preclinical trials, a single dose of WVE-007 led to significant weight loss and prevented weight regain when combined with semaglutide [5] Clinical Trial Information - The first-in-human study of WVE-007 will be a Phase 1 clinical trial focusing on safety, tolerability, pharmacokinetics, and metabolic health in adults with overweight or obesity [6]

Company Overview - Wave Life Sciences Ltd. is a clinical-stage biotechnology company focused on RNA medicines aimed at transforming human health [1][3] - The company utilizes its RNA medicines platform, PRISM®, which integrates various modalities and innovations in chemistry to address both rare and prevalent disorders [3] Upcoming Event - Paul Bolno, MD, MBA, President and CEO of Wave Life Sciences, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 9:45 a.m. PT / 12:45 p.m. ET [1] Pipeline and Research Focus - Wave Life Sciences has a diversified pipeline that includes clinical programs targeting Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency, and Huntington’s disease, along with a preclinical program in obesity [3] - The company aims to leverage its RNA-targeting modalities, which include editing, splicing, RNA interference, and antisense silencing, to develop effective treatments [3]

Company Overview - Wave Life Sciences Ltd. is a clinical-stage biotechnology company focused on RNA medicines aimed at transforming human health [3] - The company utilizes its RNA medicines platform, PRISM®, which integrates various modalities and innovations in chemistry and human genetics to develop treatments for both rare and prevalent disorders [3] - Wave's pipeline includes clinical programs targeting Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency, and Huntington's disease, along with a preclinical program in obesity [3] Upcoming Events - Paul Bolno, MD, MBA, President and CEO of Wave Life Sciences, will participate in an analyst-led fireside chat at the Jefferies London Healthcare Conference on November 20, 2024, at 4:30 p.m. GMT / 11:30 a.m. ET [1] - A live webcast of the presentation will be available on the company's Investor Relations website, with a replay accessible for a limited time after the event [2]

Financial Data and Key Metrics Changes - Revenue for Q3 2024 decreased compared to the prior year due to one-time events in the previous year related to the Takeda collaboration and a non-cash reduction in cumulative revenue under the GSK collaboration [40][41] - Net loss for Q3 2024 was $61.8 million, a significant decrease from a net income of $7.3 million in the prior year quarter [42] - Cash and cash equivalents at the end of Q3 2024 were $310.9 million, expected to fund operations into 2027 [42] Business Line Data and Key Metrics Changes - Research and development expenses increased to $41.2 million in Q3 2024 from $31.6 million in the prior year, driven by spending on the INHBE, AATD, HD, and DMD programs [41] - General and administrative expenses rose to $15 million in Q3 2024 from $13.1 million in the prior year [41] Market Data and Key Metrics Changes - The company is advancing multiple clinical programs, including WVE-N531 for DMD, WVE-003 for HD, WVE-006 for AATD, and WVE-007 for obesity, with significant milestones expected in 2025 [7][8][18][22] Company Strategy and Development Direction - The company aims to build on its RNA platform to deliver first and best-in-class RNA medicines, focusing on both rare and common diseases [6][7] - Upcoming milestones include multi-dose data from the RestorAATion-2 study in AATD and the initiation of dosing for WVE-007 in the next clinical quarter [8][10][18] - The company is exploring partnerships for its HD program, emphasizing the importance of having a clear clinical development pathway [52][100] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential for accelerated approval paths for WVE-003 and highlighted the urgency for disease-modifying therapies in HD [22][29] - The company is encouraged by initial FDA feedback regarding the use of caudate atrophy as a potential endpoint for HD progression [29][64] Other Important Information - The company has achieved significant clinical milestones, including the first-ever clinical demonstration of RNA editing in humans with WVE-006 [9][10] - The company is focused on addressing significant unmet needs in various therapeutic areas, including obesity and cardiometabolic diseases [15][13] Q&A Session Summary Question: Key efficacy assessments for AAT program - Management indicated that while there are exploratory endpoints, the focus of the study is on safety, tolerability, pharmacodynamics, and pharmacokinetics rather than efficacy outcomes [48][50] Question: Interest from strategic partners for HD program - Management noted that they are in planning phases for the study design and that owning the asset is a positive factor for potential partnerships [52] Question: Differentiation of INHBE from GLP-1s - Management highlighted that their program shows substantial reductions in visceral fat and retention of muscle mass, which could support a favorable label build [58] Question: FDA's support for biomarkers - Management confirmed that the FDA is open to the use of caudate atrophy as a biomarker for HD progression, which is encouraging for the program [63][64] Question: DMD program and accelerated approval - Management stated that the regulatory paradigm remains focused on dystrophin as a clinical surrogate endpoint, and they are optimistic about the potential for accelerated approval [104]

Wave Life Sciences (WVE) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -67.86%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.16 per share when it actually produced a loss of $0.25, delivering a surprise of -56.25%.Over the last four quarters ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-37627 WAVE LIFE SCIENCES LTD. (Exact name of registrant as specified in its charter) Singapore (State or other j ...